2cureX AB (publ) (2CUREX.ST)
SEK 0.35
(4.19%)
SEK 0.35
(4.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -32.51 Million SEK | -12.45% |
| 2022 | -27.4 Million SEK | -44.73% |
| 2021 | -18.93 Million SEK | -158.7% |
| 2020 | -7.32 Million SEK | 7.73% |
| 2019 | -7.93 Million SEK | -9.21% |
| 2018 | -7.26 Million SEK | -131.63% |
| 2017 | -3.13 Million SEK | -383.2% |
| 2016 | -649.01 Thousand SEK | -35.46% |
| 2015 | -479.1 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.77 Million SEK | 2.96% |
| 2024 Q2 | -4.77 Million SEK | 0.0% |
| 2023 Q2 | -8.15 Million SEK | -21.65% |
| 2023 FY | -30.81 Million SEK | -12.45% |
| 2023 Q4 | -4.92 Million SEK | 51.54% |
| 2023 Q3 | -10.16 Million SEK | -24.65% |
| 2023 Q1 | -6.7 Million SEK | 29.46% |
| 2022 Q2 | -5.26 Million SEK | 31.75% |
| 2022 FY | -27.4 Million SEK | -44.73% |
| 2022 Q4 | -9.5 Million SEK | -30.18% |
| 2022 Q3 | -7.3 Million SEK | -38.78% |
| 2022 Q1 | -7.7 Million SEK | -24.11% |
| 2021 Q3 | -5.42 Million SEK | 0.7% |
| 2021 Q2 | -5.46 Million SEK | -197.82% |
| 2021 Q1 | -1.83 Million SEK | 19.31% |
| 2021 FY | -18.93 Million SEK | -158.7% |
| 2021 Q4 | -6.21 Million SEK | -14.43% |
| 2020 Q3 | -810 Thousand SEK | 73.76% |
| 2020 Q2 | -3.08 Million SEK | -168.67% |
| 2020 FY | -7.32 Million SEK | 7.73% |
| 2020 Q4 | -2.27 Million SEK | -180.74% |
| 2020 Q1 | -1.14 Million SEK | 46.26% |
| 2019 FY | -7.93 Million SEK | -9.21% |
| 2019 Q1 | -1.53 Million SEK | -204.36% |
| 2019 Q3 | -1.39 Million SEK | 51.27% |
| 2019 Q4 | -2.13 Million SEK | -53.26% |
| 2019 Q2 | -2.86 Million SEK | -86.27% |
| 2018 Q1 | -2.94 Million SEK | -29.7% |
| 2018 FY | -7.26 Million SEK | -131.63% |
| 2018 Q3 | -711 Thousand SEK | 77.09% |
| 2018 Q2 | -3.1 Million SEK | -5.43% |
| 2018 Q4 | -505 Thousand SEK | 28.97% |
| 2017 Q4 | -2.26 Million SEK | -654.11% |
| 2017 FY | -3.13 Million SEK | -383.2% |
| 2017 Q1 | -1.54 Million SEK | -391.92% |
| 2017 Q2 | -1.23 Million SEK | 20.38% |
| 2017 Q3 | -301 Thousand SEK | 75.55% |
| 2016 FY | -649.01 Thousand SEK | -35.46% |
| 2016 Q4 | 529.59 Thousand SEK | 0.0% |
| 2015 FY | -479.1 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 93.025% |
| AcouSort AB (publ) | -17.08 Million SEK | -90.286% |
| Active Biotech AB (publ) | -45.8 Million SEK | 29.0% |
| Alzinova AB (publ) | -16.48 Million SEK | -97.318% |
| Amniotics AB (publ) | -30.87 Million SEK | -5.339% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -153.492% |
| BioArctic AB (publ) | 229.24 Million SEK | 114.185% |
| Camurus AB (publ) | 431.44 Million SEK | 107.537% |
| Cantargia AB (publ) | -280.02 Million SEK | 88.388% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -54.18% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -98.305% |
| Genovis AB (publ.) | 61.5 Million SEK | 152.875% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 71.305% |
| Mendus AB (publ) | -101.61 Million SEK | 68.0% |
| Kancera AB (publ) | -64.88 Million SEK | 49.887% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 703.75% |
| LIDDS AB (publ) | -40.2 Million SEK | 19.122% |
| Lipum AB (publ) | -37.17 Million SEK | 12.534% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -168.123% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 367.22% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -81.695% |
| NextCell Pharma AB | -41.95 Million SEK | 22.502% |
| OncoZenge AB (publ) | -15.9 Million SEK | -104.49% |
| Saniona AB (publ) | -95.81 Million SEK | 66.06% |
| Simris Alg AB (publ) | -37.3 Million SEK | 12.832% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 89.542% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 91.623% |
| Xintela AB (publ) | -54.08 Million SEK | 39.874% |
| Ziccum AB (publ) | -21.41 Million SEK | -51.868% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 12.282% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 81.901% |
| CombiGene AB (publ) | -35.66 Million SEK | 8.825% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 78.585% |
| Intervacc AB (publ) | -102.85 Million SEK | 68.384% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 86.919% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -7324.201% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -96.804% |
| Corline Biomedical AB | -1.8 Million SEK | -1697.568% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 81.715% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 42.771% |
| Aptahem AB (publ) | -11.11 Million SEK | -192.616% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 73.577% |
| Fluicell AB (publ) | -26.55 Million SEK | -22.46% |
| Biovica International AB (publ) | -124.82 Million SEK | 73.949% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 22.985% |
| Abliva AB (publ) | -95.5 Million SEK | 65.953% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 90.053% |
| I-Tech AB | 20.2 Million SEK | 260.956% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 96.09% |
| Cyxone AB (publ) | -22.98 Million SEK | -41.45% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 64.423% |
| Biosergen AB | -27.03 Million SEK | -20.272% |
| Nanologica AB (publ) | -75.15 Million SEK | 56.733% |
| SynAct Pharma AB | -215.81 Million SEK | 84.932% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 26.186% |
| BioInvent International AB (publ) | -330.3 Million SEK | 90.155% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -36.993% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 86.946% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -227.472% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 70.246% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -178.455% |